ASH News Daily 2013 - Day 1 - (Page B-1)
Read this issue online at
www.hematology.org/ashnewsdaily2013_saturday
Follow us on Twitter using #ASH13
SCheDuLe
7:00 a.m. - 6:00 p.m.
Registration
Ernest N. Morial Convention Center
Great Hall
7:30 - 9:00 a.m.
Education/Scientific Program
9:00 a.m. - 7:30 p.m.
Poster Session I - Viewing
Ernest N. Morial Convention Center
Halls E and G
9:30 - 11:00 a.m.
Education/Scientific Program
11:00 a.m. - 5:00 p.m.
Exhibits Open
Ernest N. Morial Convention Center
Halls B-D
11:15 a.m. - 12:15 p.m.
Career-Development Lunch Sessions
Open only to trainees wearing a blue
badge
11:30 a.m. - 12:30 p.m.
Product Theaters in Exhibit Hall
Halls B-D
2:00 - 3:30 p.m.
Education/Scientific Program
4:00 - 5:30 p.m.
Education/Scientific Program
5:30 - 7:30 p.m.
Poster Session I - Presentations
Ernest N. Morial Convention Center
Halls E and G
IN THIS SECTION
Minority Medical
Student Awards
B-5
Catching Up with
TRTH Participants
B-8
Trainee Events
and Services
B-16
International Members
Committee
B-23
Dining in the Big Easy
B-40
The Blood Journal in 2013 and Forward
Highlighting Clinical
and Scientific
Excellence
By BoB LöwenBerg, MD, PhD,
eDitor-in-Chief, anD nanCy
BerLiner, MD, DePuty eDitor
B
lood is the leading biomedical
journal in hematology. From
its early days, it has sought
to represent the full spectrum of
subdisciplines and subspecialties
in hematology. The Journal's focus
is, and has always been, on clinical
and biological, basic and applied
developments of interest in the
field.
It is our foremost and absolute
priority to deliver important, novel
scientific and educational information to our readers as promptly as
possible. With this in mind, we have
been working on maximizing the
interest of the content for our colleagues in clinical practice. Several
features serve this goal in the Jour-
nal. The recently launched Spotlight Reviews use a concise format
to highlight emerging areas of relevance to hematology, including subjects of diagnostic and therapeutic
importance. The Spotlight Reviews
on the promising new myeloma
drug pomalidomide and the diagnosis of acute pulmonary embolism
are examples.
The Review Series was launched
this year and offers collections of reviews that place new developments
on a related theme in a comprehensive scientific and clinical perspective. We hope that these reviews are
attractive to clinicians and scientists alike. Two recent Series cover
cancer-associated thrombotic disease and the emerging role of nextgeneration sequencing in hematology. We have actively continued to
publish Perspectives and Reviews
with a clinical orientation (e.g., "A
comprehensive review and analysis
of the effect of ruxolitinib therapy
on the survival of patients with myelofibrosis") as well as our Blood
Consults, the Evidence-Based Focused Reviews (e.g., "Treatment of
acquired von Willebrand syndrome
in childhood"), and our CME articles. These features should serve our
readers working in clinical practice.
The same applies to the Clinical
Recommendation and Guideline
papers that appear on a regular
basis in the Journal. The important
European LeukemiaNet recommendations for the management
of chronic myeloid leukemia have
been published, and an analogous
recommendation paper on the
management of MDS recently appeared in the Journal. The results of
major clinical trials in various areas
in hematology, obviously too many
to list here, are frequently also published in our pages.
Blood's "How I Treat" articles
have gained a special position over
the years and represent a fascinating diversity of our clinical field
and the clinical challenges that we
»» JOURNAL Page B-4
Reception Honors 2014 ASH-AMFDP Award
Winners and 2013 MMSAP Participants
T
his evening, ASH will host
the annual Promoting Minorities in Hematology Presentations and Reception. While
providing a forum to network
with colleagues, medical students,
and ASH leadership, the reception will showcase training and
research opportunities geared toward increasing the diversity of
scholars in the field of hematology.
Attendees will also learn about the
details of the Society's Minority
Medical Student Award Program
(MMSAP) and the ASH-Harold
Amos Faculty Development Program (AMFDP). The event will be
held from 6:30 to 9:30 p.m. in the
Napoleon Ballroom at the Hilton
New Orleans Riverside.
At this evening's reception, 15
MMSAP participants will present their summer research projects.
During the presentations, the 2014
ASH-AMFDP recipients, Esther Obeng,
MD, PhD, and Abner Louissaint, MD,
PhD, will also be
announced.
Dr. Obeng is an
instructor in pediatrics at Harvard
Medical School in
Boston,
working
in the laboratory
of Benjamin Ebert,
MD. Her clinical
Abner Louissaint, MD, PhD
Esther Obeng, MD, PhD
interests are in stem
cell
transplantation and bone marrow failure. Dr. Brigham and Women's Hospital in
Obeng is also an attending physi- the Department of Newborn Medician at Boston Children's Hospital cine. Upon receipt of her BS, she
in the Division of Hematology/ continued at the University of MiOncology, an attending physician ami to obtain her MD and PhD. Her
at Dana-Farber Institute in the graduate work was supported by
Department of Pediatric Oncology, and a consulting physician at
»» ASH-AMFDP Page B-3
http://www.hematology.org/ashnewsdaily2013_saturday
Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 1
Table of Contents
ASH News Daily 2013 - Day 1
https://www.nxtbookmedia.com